Nykode Therapeutics AS (VACBF)
OTCMKTS · Delayed Price · Currency is USD
0.2046
-0.0245 (-10.69%)
At close: Jun 3, 2025

Nykode Therapeutics AS Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
57886898412,6532,492
Upgrade
Market Cap Growth
-85.01%-87.30%-18.07%-68.29%6.48%-
Upgrade
Enterprise Value
-52-245286132,4662,473
Upgrade
Last Close Price
0.200.241.58---
Upgrade
PE Ratio
-----16.64
Upgrade
PS Ratio
6.919.5651.7393.1674.1811.55
Upgrade
PB Ratio
0.430.644.025.3613.6713.93
Upgrade
P/TBV Ratio
0.430.644.035.3613.6713.93
Upgrade
P/FCF Ratio
----9341.3113.83
Upgrade
P/OCF Ratio
----2296.9113.82
Upgrade
EV/Sales Ratio
--39.6267.9068.9411.46
Upgrade
EV/EBITDA Ratio
-----13.87
Upgrade
EV/EBIT Ratio
-----13.87
Upgrade
EV/FCF Ratio
1.08---8682.6113.73
Upgrade
Debt / Equity Ratio
0.020.030.030.040.040.00
Upgrade
Debt / EBITDA Ratio
-----0.00
Upgrade
Debt / FCF Ratio
----25.250.00
Upgrade
Asset Turnover
0.050.050.060.040.141.64
Upgrade
Quick Ratio
16.9312.787.945.418.1217.36
Upgrade
Current Ratio
16.9312.878.045.448.1617.38
Upgrade
Return on Equity (ROE)
-17.30%-25.25%-21.42%-24.35%-5.05%145.07%
Upgrade
Return on Assets (ROA)
-14.87%-16.70%-16.90%-13.64%-2.72%84.59%
Upgrade
Return on Capital (ROIC)
-16.72%-19.08%-21.38%-18.27%-3.54%107.72%
Upgrade
Return on Capital Employed (ROCE)
-----82.20%
Upgrade
Earnings Yield
-44.26%-44.34%-5.10%-5.08%-0.36%6.01%
Upgrade
FCF Yield
-83.43%-58.58%-14.30%-2.78%0.01%7.23%
Upgrade
Dividend Yield
-36.55%----
Upgrade
Buyback Yield / Dilution
-5.17%-8.66%-3.58%-1.32%3.31%-1.14%
Upgrade
Total Shareholder Return
-27.89%-3.58%-1.32%3.31%-1.14%
Upgrade
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.